Tazemetostat, a selective EZH2 inhibitor, in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: A phase 1 trial

Authors

Peter J Oppelt, Washington University School of Medicine in St. Louis
Sidharth V Puram, Washington University School of Medicine in St. Louis
Jingxia Liu, Washington University School of Medicine in St. Louis
Jessica C Ley, Washington University School of Medicine in St. Louis
Douglas Adkins, Washington University School of Medicine in St. Louis

Journal

Cancers

Publication Date

1-27-2025

Volume

17

Issue

3

First Page

437

Document Type

Open Access Publication

DOI

10.3390/cancers17030437

Rights and Permissions

Oppelt PJ, Puram SV, Liu J, Ley JC, Adkins D. Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial. Cancers (Basel). 2025 Jan 27;17(3):437. doi: 10.3390/cancers17030437 Copyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/ licenses/by/4.0/).

Recommended Citation

Oppelt, Peter J; Puram, Sidharth V; Liu, Jingxia; Ley, Jessica C; and Adkins, Douglas, "Tazemetostat, a selective EZH2 inhibitor, in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: A phase 1 trial." Cancers. 17, 3. 437 (2025).
https://digitalcommons.wustl.edu/oa_4/4817

Department

ICTS (Institute of Clinical and Translational Sciences)